The first description of docetaxel-induced recall inflammatory skin reaction after previous drug extravasation

Annals of Pharmacotherapy

Volumn 45, Issue 2, 2011, Pages

  Kramer, Frauke ^a   Schippert, Cordula ^a   Rinnau, Franziska ^a   Hillemanns, Peter ^a   Park Simon, Tjoung Won ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Docetaxel; Drug extravasation; Recall skin reaction

Indexed keywords

ANALGESIC AGENT; ANTIESTROGEN; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CEFAZOLIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; HYALURONIDASE; IBANDRONIC ACID; NAVELBINE; PACLITAXEL; STEROID; TAXANE DERIVATIVE; TAXOID;

AGED; AREA UNDER THE CURVE; ARTICLE; AXILLARY LYMPH NODE EXTIRPATION; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CASE REPORT; DERMATITIS; DISEASE SEVERITY; DRUG EXTRAVASATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ERYTHEMA; FEMALE; HUMAN; INJECTION SITE EXTRAVASATION; INTRADUCTAL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE DISSECTION; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; PERIPHERAL VEIN; PLEURA METASTASIS; PRIORITY JOURNAL; RECALL DERMATITIS; SKIN INJURY; SOFT TISSUE INJURY; STEROID THERAPY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMICALLY INDUCED; CONTRAST MEDIUM EXTRAVASATION; DRUG ERUPTIONS; METASTASIS; RECURRENT DISEASE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CARCINOMA, DUCTAL, BREAST; DRUG ERUPTIONS; ERYTHEMA; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; FEMALE; HUMANS; NEOPLASM METASTASIS; RECURRENCE; TAXOIDS;

EID: 79951904087     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P440     Document Type: Article

References (14)

1. Quincy C, Vincent M, Logan M, Mackay JA, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer 2005;50:355-74.
2. Von Hoff DD. The taxoids: same roots, different drugs. Semin Oncol 1997;24:S13-3-S13-10.
3. Zimmermann GC, Keeling JH, Burris HA, et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995;131:202-6.
4. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999;40:367-98. (Pubitemid 29115299)
5. Chew L, Shih Lee Chuen V. Cutaneous reaction associated with weekly docetaxel administration. J Oncol Pharm Pract 2009;15:29-34.
6. Morkas M, Fleming D, Hahl M. Case 2. Radiation recall associated with docetaxel. J Clin Oncol 2002;20:867-9. (Pubitemid 34111398)
7. Borgia F, Guarneri C, Guaneri F, Vaccaro M. Radiation recall dermatitis after docetaxel administration: absolute indication to replace the drug? Br J Dermatol 2005;153:674-5.
8. Rowinsky EK, Eisenhauer EA, Chaudry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993;20:1-15. (Pubitemid 23239390)
9. McGuire WP, Rowinsky EK, Rosenheim NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-9. (Pubitemid 19204753)
10. Shapiro J, Richardson GE. Paclitaxel-induced "recall" soft tissue injury occurring at the site of previous extravasation with subsequent intravenous treatment in a different limb (letter). J Clin Oncol 1994;12:2237-8.
11. Mechan JL, Sporn JR. Case report of taxol administration via central vein producing a recall reaction at a site of prior taxol extravasation. J Natl Cancer Inst 1994;86:1250-1. (Pubitemid 24253703)
12. Du Bois A, Kommos FGM, Pfisterer J, Lück H J, Meerpohl HG. Paclitaxel-induced "recall" soft tissue ulcerations occurring at the site of previous subcutaneous administration of paclitaxel in low doses. Gynecol Oncol 1996;60:94-6.
13. Saini A, Berruti A, Sperone P, et al. Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug extravasation. Lancet Oncol 2006;7:186-7. (Pubitemid 43159506)
14. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. (Pubitemid 12149145)